UCB (OTCMKTS:UCBJF) Trading Down 6.2% – What’s Next?

UCB SA (OTCMKTS:UCBJF)’s stock price dropped 6.2% on Friday . The stock traded as low as $284.3501 and last traded at $284.3501. 6 shares changed hands during trading, a decline of 99% from the average session volume of 698 shares. The stock had previously closed at $303.29.

Analysts Set New Price Targets

A number of research analysts recently issued reports on UCBJF shares. The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a report on Monday, February 16th. Stephens restated an “overweight” rating on shares of UCB in a research report on Thursday, January 15th. Barclays reaffirmed an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of UCB in a report on Monday, December 8th. Finally, Wolfe Research assumed coverage on UCB in a report on Monday, February 23rd. They issued an “outperform” rating for the company. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, UCB has an average rating of “Buy”.

UCB Trading Down 6.2%

The company has a fifty day moving average of $311.36 and a 200 day moving average of $285.34. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.